Remove 2022 Remove Clinical Trials Remove Safety
article thumbnail

The Scott of Pot At It Again. Cann Group aiming for over-the-counter CBD approval in late 2022

Cannabis Law Report

Phase I clinical trial of the Satipharm CBD capsules in which results demonstrated the safety and high performance of the oral capsule technology, including the superior delivery profile of cannabidiol (CBD) compound to trial subjects. Cann Group (ASX: CAN) aiming for over-the-counter CBD approval in late 2022.

article thumbnail

CBD Market Report

Project CBD

Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: [link] Accessed October 17, 2022. Accessed October 17, 2022. February 2, 2022.

CBD 144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cannabis as a cancer cure: what is the research and where is it going?

The Cannigma

To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. While RSO has been subject to increased popularity in treating certain types of cancers, no clinical trials have tested the safety or efficacy of RSO in humans, meaning that all evidence is anecdotal.

article thumbnail

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

article thumbnail

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

Cannabis Law Report

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

article thumbnail

Answer of the Day for Mar 30, 2022

TheAnswerPage

Has the National Institute of Drug Abuse (NIDA) recently provided funding for a clinical trial evaluating the efficacy of a CBD product as an opioid-sparing agent for patients with radiculopathic pain? Safety and tolerability of CBD will also be assessed throughout the trial.

article thumbnail

Study Demonstrates Power of Using Ketamine for Parkinson’s Disease

Veriheal

Following the successful experiment into the potential safety and efficacy of using ketamine for Parkinson’s patients, the university proceeded to sign an exclusive licensing partnership with Pharmather Inc. , At the current time, researchers are busy carrying out a small-scale Phase I clinical trial into ketamine for PD.